About
Research
Patient Care
Education
Community
Jul 25, 2023
Just Published NUTRIENT Trial: Mediterranean Diet Intervention in MPNs
Dr. Fleischman, an MPN specialist at University of California, Irvine, is a leader in connecting the fresh foods Mediterranean diet with symptom improvement in people living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). In this latest study, she and her collaborators examined how effective education would be in changing MPN patients’ eating habits to align with the Mediterranean diet. Dr. Fleischman et al reported results of the NUTRIENT trial, based on work funded in part by MPNRF through a 2017-2019 Challenge award. The research established that a Mediterranean diet intervention is in fact feasible in the MPN patient population and can improve symptom burden.
Jul 24, 2023
Bridging the Gap: Latinx Children with Cancer, Culturally Appropriate Support for Families
Fortier’s work has shown that the pain management treatment of Latinx children – and their outcomes – are too often inadequate when compared to non-Latinx white children. Besides the immediate impact of not assisting a child in need, researchers have found that there are long term consequences to poorly managed pain that amplify health inequities for Latinx patients when they are adults including changes in their physiological responses to pain and avoidance of preventive healthcare to support wellness.
July 12, 2023 Bulletin
Events, Announcements & Funding Opportunities
July 12, 2023
Jun 28, 2023
UCI Health Named One of America's Best Cancer Hospitals by Newsweek
UCI Health has been recognized as one of America’s Best Cancer Hospitals by Newsweek in its inaugural rankings of the specialty, highlighting our commitment to exceptional cancer care. The UCI Health Chao Family Comprehensive Cancer Center is one of only 53 centers designated as comprehensive by the National Cancer Institute (NCI) and the only one in Orange County. The cancer center offers one of the region’s largest early phase cancer clinical trials programs.
June 28, 2023 Bulletin
June 28, 2023
When young people survive cancer, their mental-health struggles are often just beginning
“Young cancer survivors suffer from numerous late effects,” said Joel Milam, a professor in the department of epidemiology and biostatistics at the University of California, Irvine and co-director of the Southern California Center for Young Adult Cancer Survivorship Research, who was not involved in the study. “Much of the focus historically has been on medical late effects, like higher risk for cardiovascular disease or [cancer] recurrence. The fact that there are also mental health implications is not surprising at all.”
Jun 22, 2023
Breakthroughs offer hope for vitiligo patients
In 2018, Dr. Anand K. Ganesan (above left) opened a vitiligo specialty practice lab at the UCI Health Beckman Laser Institute & Medical Clinic, hoping to find new therapies to reverse the disfiguring skin disorder. Now, the lab has produced a topical cream called ruxolitinib, the first therapy approved by the U.S. Federal Drug Administration that restores pigment in vitiligo patients. The FDA also recently gave breakthrough device approval for RECELL®, a one-time therapy using the patient’s healthy cells to stimulate lasting repigmentation in stable vitiligo.
Jun 21, 2023
Cancer researchers learn about big data analysis using Anvil
The BigCare workshop, otherwise known as the “Big Data Training for Cancer Research,” is a program funded by the National Cancer Institute (NCI). The purpose of the workshop is to help cancer researchers develop the requisite skills for managing, visualizing, analyzing, and integrating various types of “omics” data in cancer studies. BigCare was founded in 2020 by Min Zhang, PhD, a professor of epidemiology and biostatistics at the University of California, Irvine’s Program in Public Health, as well as the biostatistics shared resources director for the UCI Chao Family Comprehensive Cancer Center.
Jun 20, 2023
FDA Approves New Drug Combo For Prostate Cancer
Alexandre Chan, PharmD, MPH, professor of clinical pharmacy at the School of Pharmacy & Pharmaceutical Sciences at University of California, Irvine is similarly excited about the prospect of this combination of medications being better understood and implemented. “I think that’s good news for patients, in the sense that there are additional therapies that we can use at first line and [they] have demonstrated that if you have the proper mutations, you get much better progression free and also overall survival.”
Jun 14, 2023
Adjusting Your Body Clock May Stave Off Cancer
For some time now epidemiological studies of night-shift workers have linked disruptions in circadian rhythms to cancer and other diseases. … “We're starting to understand the reasons these things happen,” says Selma Masri, a circadian biologist and assistant professor at the University of California, Irvine, who has shown how circadian disruption pushes colon cancer progression by interfering with the way certain genes are expressed.